Codexis, Inc. (CDXS)
| Previous Close | 2.8000 |
| Open | 2.7700 |
| Bid | 2.7500 x 600 |
| Ask | 2.8400 x 100 |
| Day's Range | 2.7100 - 2.8700 |
| 52 Week Range | 1.4500 - 4.9100 |
| Volume | |
| Avg. Volume | 590,520 |
| Market Cap | 196.147M |
| Beta (5Y Monthly) | 2.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Codexis to Report First Quarter 2024 Financial Results on May 2
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relation
- GlobeNewswire
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platformREDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s Strategic Advisory Board (SAB). Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences, a bio-performance company developing RNA-based solutions for agricu
- GlobeNewswire
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End of 2026 2024 to Focus on Securing Early Access Customers for ECO Synthesis™ Manufacturing Platform, Launch of Double-stranded RNA Ligase and Return to Growth for Pharmaceutical Manufacturing REDWOOD CITY, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Codex
